Human herpes virus 8-negative primary effusion lymphoma with BCL6 rearrangement in a patient with idiopathic CD4 positive T-lymphocytopenia.
Primary effusion lymphoma (PEL) was initially designated as a body-cavity-based lymphoma and recognized as a distinct clinical entity without a contiguous tumor mass. PEL was first reported in patients with acquired immunodeficiency syndrome (AIDS) and the distinctive feature of PEL originally reported as a B-cell neoplasm characterized by infection of the tumor cells by human herpes virus 8 (HHV-8). However, there have recently been several reports of PEL in patients without human immunodeficiency virus (HIV) or HHV-8 infection.
Niino
D
D
Department of Pathology, National Nagasaki Medical Center, 2-1001-1, Kubara, Omura, Nagasaki 856-8562, Japan. niino522@yahoo.co.jp
Tsukasaki
K
K
Torii
K
K
Imanishi
D
D
Tsuchiya
T
T
Onimaru
Y
Y
Tsushima
H
H
Yoshida
S
S
Yamada
Y
Y
Kamihira
S
S
Tomonaga
M
M
D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D015704:CD4 Antigens / Q000096:biosynthesis*; D004268:DNA-Binding Proteins / Q000235:genetics*; D004417:Dyspnea / Q000175:diagnosis; D015321:Gene Rearrangement; D015658:HIV Infections / Q000175:diagnosis; D019288:Herpesvirus 8, Human / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D016130:Immunophenotyping; D054685:Lymphoma, Primary Effusion / Q000150:complications / Q000235:genetics* / Q000628:therapy; D008231:Lymphopenia / Q000150:complications / Q000628:therapy*; D008297:Male; D010490:Pericardial Effusion; D051560:Proto-Oncogene Proteins c-bcl-6; D013601:T-Lymphocytes / Q000378:metabolism*
D000970:Antineoplastic Agents; C084103:BCL6 protein, human; D015704:CD4 Antigens; D004268:DNA-Binding Proteins; D051560:Proto-Oncogene Proteins c-bcl-6